A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism

Anders Krarup(Janssen (Netherlands)), Daphné Truan(Janssen (Netherlands)), Polina Furmanova-Hollenstein(Janssen (Netherlands)), Lies Bogaert(Janssen (Netherlands)), Pascale Bouchier(Janssen (Netherlands)), Ilona J. M. Bisschop(Janssen (Netherlands)), Myra N. Widjojoatmodjo(Janssen (Netherlands)), Roland Zahn(Janssen (Netherlands)), Hanneke Schuitemaker(Janssen (Netherlands)), Jason S. McLellan(Dartmouth College), Johannes P. M. Langedijk(Janssen (Netherlands))
Nature Communications
September 3, 2015
Cited by 387Open Access
Full Text

Abstract

Respiratory syncytial virus (RSV) causes acute lower respiratory tract infections and is the leading cause of infant hospitalizations. Recently, a promising vaccine antigen based on the RSV fusion protein (RSV F) stabilized in the native prefusion conformation has been described. Here we report alternative strategies to arrest RSV F in the prefusion conformation based on the prevention of hinge movements in the first refolding region and the elimination of proteolytic exposure of the fusion peptide. A limited number of unique mutations are identified that stabilize the prefusion conformation of RSV F and dramatically increase expression levels. This highly stable prefusion RSV F elicits neutralizing antibodies in cotton rats and induces complete protection against viral challenge. Moreover, the structural and biochemical analysis of the prefusion variants suggests a function for p27, the excised segment that precedes the fusion peptide in the polypeptide chain.


Related Papers

No related papers found

Powered by citation graph analysis